18 completed, 4 active not recruiting, 4 recruiting, 2 unknown. 9 Not applicable, 6 Phase 1, 6 Phase 2, 6 Phase 3.
Follow Multiple Sclerosis, Primary Progressive: new trials by email Literature Review of Multiple Sclerosis, Primary Progressive trials Research Report on Multiple Sclerosis, Primary Progressive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis Orca-Q, myeloablative regimen - Primary Progressive Multiple Sclerosis, Multiple Sclerosis | Phase 1 | Not yet recruiting | Stanford University | 10 | 2025-03-01 | 2025-03-28 |
| Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland) All participants will be asked to provide data and samples for collection and analysis. - Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Recruiting | University Hospital, Basel, Switzerland | 100 | 2024-12-10 | 2025-12-26 | |
| PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF PIPE-791 - Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis | Phase 1 | Completed | Contineum Therapeutics | 16 | 2024-12-09 | 2025-08-06 |
| KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis KYV-101, Standard lymphodepletion regimen, Anti-CD20 mAB - Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive | Phase 2 | Active not recruiting | Kyverna Therapeutics | 120 | 2024-09-20 | 2025-01-13 |
| A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen - Multiple Sclerosis, Multiple Sclerosis, Primary Progressive | Phase 1 | Recruiting | Stanford University | 12 | 2024-04-10 | 2026-02-27 |
| The Effects of In-phase Bilateral Exercise in People with Progressive Multiple Sclerosis In-phase Bilateral Exercise, Conservative exercises - Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive | Not applicable | Completed | Cyprus University of Technology | 20 | 2023-10-02 | 2024-09-19 |
| Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy Clemastine Fumarate, Placebo - Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting | Phase 1 / Phase 2 | Recruiting | University of California, San Francisco | 74 | 2023-08-01 | 2026-07-02 |
| An Observational Biomarker Study in Multiple Sclerosis (MS) Patients Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive | Completed | LAPIX Therapeutics Inc. | 137 | 2023-03-28 | 2024-06-11 | |
| MUSCLE - Nordic Walking in MUltiple SCLErosis Nordic Walking (NWG), Free Walking (FWG), Health Education (HEG) - Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis | Not applicable | Unknown | Leonardo A. Peyré-Tartaruga | 60 | 2022-08-02 | 2022-05-23 |
| Exercise Effects in Multiple Sclerosis Exercise Group 1, Exercise Group 2, Exercise Group 3 - Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Relapsing-Remitting | Not applicable | Unknown | University of Regina | 69 | 2022-06-15 | 2024-02-15 |
| Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis N-acetyl cysteine, Placebo - Multiple Sclerosis, Multiple Sclerosis, Primary Progressive | Phase 2 | Active not recruiting | Emmanuelle Waubant, MD PhD | 98 | 2022-02-16 | 2026-03-11 |
| MS-ResearchBiomarkerS Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Recruiting | Cedars-Sinai Medical Center | 1000 | 2021-11-11 | 2024-02-06 | |
| Motor Asymmetry in Progressive Multiple Sclerosis Patients Magnetic Resonance Imaging, Neurological examination, Multiple Sclerosis Functional Composite - Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive | Completed | Rennes University Hospital | 46 | 2021-11-03 | 2026-03-19 | |
| A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis Fenebrutinib, Ocrelizumab, Placebo matched to ocrelizumab - Multiple Sclerosis, Primary Progressive | Phase 3 | Active not recruiting | Hoffmann-La Roche | 985 | 2020-10-26 | 2026-09-17 |
| A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis Ocrelizumab, Placebo - Multiple Sclerosis, Primary Progressive | Phase 3 | Active not recruiting | Hoffmann-La Roche | 1013 | 2019-08-12 | 2026-02-23 |
| Improving Cognition in People With Progressive Multiple Sclerosis Using Aerobic Exercise and Cognitive Rehabilitation Cognitive Rehabilitation, Sham Exercise, Sham Cognitive Rehabilitation - Multiple Sclerosis, Primary Progressive, Cognitive Impairment | Not applicable | Completed | Sunnybrook Health Sciences Centre | 309 | 2019-03-18 | 2023-11-08 |
| Cognition Evolution and MRI Markers in PPMS Patients on 2 Years Clinical assessment, Ecological evaluation, Neuropsychological evaluation - Multiple Sclerosis, Primary Progressive | Not applicable | Completed | University Hospital, Bordeaux | 66 | 2018-09-24 | 2026-08-04 |
| Follow-up Study of the Effectiveness of Virtual Reality Therapy in MS Patients Training groupe, PNF, Spinning grp - Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Primary Progressive | Not applicable | Completed | Somogy Megyei Kaposi Mór Teaching Hospital | 4 | 2018-04-06 | 2022-04-05 |
| The Effect of Neurorehabilitation Therapy on Postural Control, Mobility and Quality of Life in Multiple Sclerosis Patients Neurorehabilitation, Physiotherapy - Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Primary Progressive | Not applicable | Completed | Somogy Megyei Kaposi Mór Teaching Hospital | 2 | 2018-02-05 | 2020-04-28 |
| Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis Insulin, Placebo (Sterile diluent) - Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive | Phase 1 / Phase 2 | Completed | Johns Hopkins University | 105 | 2017-12-01 | 2023-03-10 |
Showing 20 of 29. Sign in to see all of them.
Multiple Sclerosis, Chronic Progressive (29) · Multiple Sclerosis (16) · Multiple Sclerosis, Relapsing-Remitting (9) · Autoimmune Diseases (3) · Autoimmune Diseases of the Nervous System (2) · Cognitive Dysfunction (2) · Nervous System Diseases (2) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Idiopathic Pulmonary Fibrosis (1) · Immune System Diseases (1) · Mobility Limitation (1) · Motor Activity (1) · Movement Disorders (1) · Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (1)
Chronic Disease (29) · Disease Attributes (29) · Pathological Conditions, Signs and Symptoms (29) · Demyelinating Autoimmune Diseases, CNS (28) · Demyelinating Diseases (28) · Immune System Diseases (28) · Pathologic Processes (28) · Autoimmune Diseases of the Nervous System (27) · Nervous System Diseases (27) · Autoimmune Diseases (26) · Multiple Sclerosis (13) · Central Nervous System Diseases (2) · Cognition Disorders (2) · Mental Disorders (2) · Neurocognitive Disorders (2)
ocrelizumab (4) · Exercise (2) · 4-Aminopyridine (1) · Acetylcysteine (1) · Bendamustine Hydrochloride (1) · Busulfan (1) · Clemastine (1) · Cognitive Training (1) · Fluorodeoxyglucose F18 (1) · Histamine Antagonists (1) · Hydroxychloroquine (1) · Insulin (1) · Magnetic Resonance Spectroscopy (1) · Neurologic Examination (1) · Neurological Rehabilitation (1)
Hoffmann-La Roche (3) · Johns Hopkins University (2) · Somogy Megyei Kaposi Mór Teaching Hospital (2) · Stanford University (2) · AB Science (1) · Assistance Publique - Hôpitaux de Paris (1) · Biogen (1) · Cedars-Sinai Medical Center (1) · Contineum Therapeutics (1) · Cyprus University of Technology (1) · Emmanuelle Waubant, MD PhD (1) · Genentech, Inc. (1) · Kyverna Therapeutics (1) · LAPIX Therapeutics Inc. (1) · Leonardo A. Peyré-Tartaruga (1)
United States (13) · Canada (7) · France (7) · Bulgaria (4) · Germany (4) · Hungary (4) · Poland (4) · Spain (4) · United Kingdom (4) · Australia (3) · Brazil (3) · Greece (3) · Italy (3) · Mexico (3) · Portugal (3)
Scott Newsome, DO (2) · Anne Kerbrat, MD (1) · Anthony Feinstein, MD (1) · Ari J Green, MD, MCR (1) · Brooke Guerrero, MD (1) · Bruno Stankoff (1) · Cameron Mang, PhD (1) · Cristina Granziera, Prof. (1) · Dimitris Sokratous (1) · Ellen Mowry, MD, MCR (1) · Heba A. Kalifa, Ph.D (1) · Jeffrey Dunn, MD (1)
PMID 12324550, PMID 12525714, PMID 12527959, PMID 20023002, PMID 20156050, PMID 21056491, PMID 23552330, PMID 23869824, PMID 24262162, PMID 27017543, PMID 28002688, PMID 28017241, PMID 28178885, PMID 28915856, PMID 30155979, PMID 30157388, PMID 30415593, PMID 30844920, PMID 32443981, PMID 32813051, PMID 32911307, PMID 33054533, PMID 33129442, PMID 33410109, PMID 33724638, PMID 34123427, PMID 34197674, PMID 34595972, PMID 34741240, PMID 34780079, PMID 34803726, PMID 35084560, PMID 35190477, PMID 35672926, PMID 35939096, PMID 36163349, PMID 36182028, PMID 36214614, PMID 36229188, PMID 36436069, PMID 36792367, PMID 36881147, PMID 36933030, PMID 37291448, PMID 37537928, PMID 37652990, PMID 37739574, PMID 37916484, PMID 38071574, PMID 38129896
2023 (2), 2015 (1), 2018 (1), 2019 (1), U01NS082329 (1)